Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ziprasidone Mesylate

FDA-approved product (powder, intramuscular), marketed as Geodon, Ziprasidone Hydrochloride, Ziprasidone Mesylate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ziprasidone Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Agitation
  • Bipolar disorder
  • Bipolar I disorder
  • Cardiac arrhythmia
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia
  • Ventricular tachycardia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Indole derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ziprasidone Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ziprasidone Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes

    NCT00288353 · start 2006-01

    Registered record
    Registry ID
    NCT00288353
    Conditions
    Schizophrenia; Schizoaffective Disorder; Bipolar Disorder
    Interventions
    aripiprazole (Abilify); ziprasidone (Geodon)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2006-01
    Completion
    2008-12
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder; Bipolar Disorder
    Interventionaripiprazole (Abilify); ziprasidone (Geodon)
    PhasePhase 3
    Registry statusTerminated

  • Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

    NCT00254202 · start 2005-11-18

    Registered record
    Registry ID
    NCT00254202
    Conditions
    Schizophrenia
    Interventions
    Iloperidone; Ziprasidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-11-18
    Completion
    2007-03-21
    Enrolment
    593

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionIloperidone; Ziprasidone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis

    NCT02305823 · start 2005-10

    Registered record
    Registry ID
    NCT02305823
    Conditions
    Schizophrenia; Psychotic Disorders
    Interventions
    Aripiprazole; Quetiapine; Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-10
    Completion
    2014-05
    Enrolment
    203

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Psychotic Disorders
    InterventionAripiprazole; Quetiapine; Ziprasidone
    PhasePhase 4
    Registry statusCompleted

  • Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression

    NCT00237666 · start 2005-02

    Registered record
    Registry ID
    NCT00237666
    Conditions
    Bipolar II Disorder; Major Depressive Episode
    Interventions
    Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-02
    Completion
    2008-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar II Disorder; Major Depressive Episode
    InterventionZiprasidone
    PhasePhase 4
    Registry statusCompleted

  • Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus

    NCT00351000 · start 2005-01

    Registered record
    Registry ID
    NCT00351000
    Conditions
    Schizophrenia
    Interventions
    Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-01
    Completion
    2007-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionZiprasidone
    PhasePhase 4
    Registry statusCompleted

  • Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions

    NCT01581879 · start 2004-11

    Registered record
    Registry ID
    NCT01581879
    Conditions
    Healthy
    Interventions
    Ziprasidone Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-11
    Completion
    2005-01
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionZiprasidone Hydrochloride
    PhasePhase 1
    Registry statusCompleted

  • A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients

    NCT00645372 · start 2004-07

    Registered record
    Registry ID
    NCT00645372
    Conditions
    Schizophrenia
    Interventions
    Risperidone; Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-07
    Completion
    2005-05
    Enrolment
    242

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionRisperidone; Ziprasidone
    PhasePhase 3
    Registry statusCompleted

  • Ziprasidone in the Treatment of Borderline Personality Disorder

    NCT00635921 · start 2004-03

    Registered record
    Registry ID
    NCT00635921
    Conditions
    Borderline Personality Disorder
    Interventions
    ziprasidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-03
    Completion
    2006-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBorderline Personality Disorder
    Interventionziprasidone; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness

    NCT00199940 · start 2003-12

    Registered record
    Registry ID
    NCT00199940
    Conditions
    Schizophrenia; Affective Disorders; Psychotic Disorder; Psychotic Mood Disorder
    Interventions
    Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-12
    Completion
    2007-04
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Affective Disorders; Psychotic Disorder; Psychotic Mood Disorder
    InterventionZiprasidone
    PhasePhase 4
    Registry statusCompleted

  • Risperdal Consta for Bipolar Disorder

    NCT00177164 · start 2003-11

    Registered record
    Registry ID
    NCT00177164
    Conditions
    Bipolar I Disorder
    Interventions
    Injectable Risperidone (Consta) or oral antipsychotic
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-11
    Completion
    2009-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Disorder
    InterventionInjectable Risperidone (Consta) or oral antipsychotic
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

    NCT00650429 · start 2003-10

    Registered record
    Registry ID
    NCT00650429
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-10
    Completion
    2005-05
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionZiprasidone
    PhasePhase 4
    Registry statusCompleted

  • Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder

    NCT00395031 · start 2003-09

    Registered record
    Registry ID
    NCT00395031
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2003-09
    Completion
    2010-01
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionZiprasidone
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study

    NCT00645320 · start 2003-08

    Registered record
    Registry ID
    NCT00645320
    Conditions
    Pyschotic Disorders
    Interventions
    Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-08
    Completion
    2004-08
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPyschotic Disorders
    InterventionZiprasidone
    PhasePhase 4
    Registry statusCompleted

  • Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.

    NCT00239109 · start 2003-04

    Registered record
    Registry ID
    NCT00239109
    Conditions
    Schizophrenia
    Interventions
    Ziprasidone; Olanzapine; Scales; measures of the body (Weight...); Serum analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-04
    Completion
    2007-02
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionZiprasidone; Olanzapine; Scales; measures of the body (Weight...) +1 more
    PhasePhase 4
    Registry statusCompleted

  • Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study

    NCT00145444 · start 2003-03

    Registered record
    Registry ID
    NCT00145444
    Conditions
    Schizophrenia; Psychotic Disorders
    Interventions
    olanzapine; ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-03
    Completion
    2005-11
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Psychotic Disorders
    Interventionolanzapine; ziprasidone
    PhasePhase 3
    Registry statusCompleted